outcome of the Board meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved integrated audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025. Standalone revenue from operations rose about 6.8% to Rs. 7,268.92 lakhs (from Rs. 6,803.65 lakhs last year), but the company swung to a net loss of Rs. 1,377.98 lakhs versus a small profit of Rs. 5.32 lakhs last year, with EPS at negative Rs. 114.52. Cash and equivalents collapsed from Rs. 1,649 lakhs to just Rs. 36 lakhs, even as operating cash flow turned positive at Rs. 227.51 lakhs. Statutory auditor G. Joseph & Associates issued a qualified opinion because a Rs. 3.85 lakh bank balance could not be confirmed, plus an emphasis of matter on restatement of prior-year figures under Ind AS 8. The board also appointed a new Company Secretary (Ms. Priyanka Gangwar), new internal auditor (Mr. Alphonse Scaria), and re-appointed G. Joseph as tax auditor. It approved nearly doubling the ESOP pool from 6,66,640 to 12,03,245 units, subject to shareholder approval.
Shareholders should note the sharp swing into losses and the steep fall in cash reserves despite revenue growth, signalling cost pressures (employee costs nearly doubled to Rs. 3,551 lakhs). An EGM on June 18 will seek ratification of a material related-party transaction with Ayurvedagram Heritage Wellness Centre that already exceeded prescribed limits in FY25, plus ESOP dilution — both warrant attention before voting.